bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
| Revenue (TTM) | $5.90M |
| Gross Profit (TTM) | $2.04M |
| EBITDA | $-11.97M |
| Operating Margin | -220.80% |
| Return on Equity | -1860.00% |
| Return on Assets | -125.10% |
| Revenue/Share (TTM) | $23.20 |
| Book Value | $8.34 |
| Price-to-Book | 1.25 |
| Price-to-Sales (TTM) | 0.80 |
| EV/Revenue | 0.636 |
| EV/EBITDA | -0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 19.00% |
| Shares Outstanding | 600,740 |
| Float | 532,260 |
| % Insiders | 0.82% |
| % Institutions | 5.62% |
Volatility is currently expanding
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
Shares of BioAffinity Technologies Inc. (NASDAQ:BIAF) are surging Thursday afternoon following the grant of a key Hong Kong patent for its CyPath Lung diagnostic. The rally is also boosting BioAffinity's Warrants (NASDAQ:BIAFW), up nearly 20% late Thursday.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #AvMEDICAL--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
JERSEY CITY, N.J., Aug. 14, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock.
JERSEY CITY, N.J., , Aug. 13, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with two warrants to purchase up to an aggregate 16,924,054 shares of common stock, in a private placement offering priced at-the-market under Nasdaq rules.
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIAF and any ticker you trade — then tracks every position and per-strategy win rate.
